Filing summary
Entity and period: The supplied filing is Zafgen, Inc.’s Form 10-K for the fiscal year ended December 31, 2016, filed March 10, 2017. This does not match the request metadata identifying Larimar Therapeutics, Inc.; the figures and disclosures below are for Zafgen. Financial amounts are in U.S. dollars.
Business context and reporting period
Zafgen was a clinical-stage biopharmaceutical company developing MetAP2 inhibitors for metabolic diseases, including obesity and type 2 diabetes. Its lead candidate, injectable ZGN-1061, was in a Phase 1 trial in the Netherlands: single-dose dosing was complete and multiple-dose dosing was ongoing. The company had no approved products or product revenue.
Financial results and liquidity
| Metric | FY 2016 | FY 2015 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $39.9 million | $54.6 million |
| General and administrative expense | $18.3 million | $19.2 million |
| Total operating expenses / operating loss | $58.2 million / $(58.2) million | $73.8 million / $(73.8) million |
| Net loss | $(57.9) million | $(74.3) million |
| Basic and diluted loss per share | $(2.12) | $(2.78) |
| Operating cash used | $(52.0) million | $(59.6) million |
| Cash, cash equivalents and marketable securities at year-end | $129.2 million | $185.1 million |
| Working capital at year-end | $121.0 million | $171.6 million |
Margins are not meaningful because the company had no revenue. At December 31, 2016, total assets were $131.6 million and total liabilities were $9.9 million. Notes payable were $3.6 million, classified as current; the remaining principal was scheduled for repayment in 2017. The filing states cash resources were expected to fund operations for at least one year from the filing’s issuance date.
Fourth-quarter 2016 revenue was zero, operating expenses were $10.5 million, net loss was $10.4 million and loss per share was $0.38. In fourth-quarter 2015, net loss was $23.2 million and loss per share was $0.85.
Material changes versus the prior year
- Net loss narrowed by $16.4 million year over year, while total operating expenses fell by $15.6 million.
- R&D expense declined by $14.7 million, primarily following the suspension of beloranib and ZGN-839 development. Spending on second-generation MetAP2 inhibitors, primarily ZGN-1061, increased by $1.8 million.
- Operating cash use decreased by $7.6 million. Year-end cash, cash equivalents and marketable securities declined by $55.9 million; 2015 included $130.0 million of net follow-on offering proceeds, while 2016 had no public offering proceeds.
- The company reduced its workforce by approximately 31% as part of its strategic refocus. It recorded $1.4 million in restructuring costs, including $1.2 million cash costs, and reported a $0.4 million restructuring reserve at year-end.
Outlook, risks, contingencies and unusual items
- Management expected to complete ZGN-1061 Phase 1 dosing by the end of first-quarter 2017 and report results early in second-quarter 2017. Subject to positive results, it planned to seek an FDA IND for U.S. clinical development and conduct a Phase 2 trial in Australia. These are forward-looking plans, not assured outcomes.
- The principal clinical risk is whether ZGN-1061 can demonstrate an acceptable safety profile, particularly regarding thrombosis. Beloranib’s IND had been placed on full FDA clinical hold in December 2015 following an imbalance in thrombotic events; Zafgen discontinued its development in July 2016. ZGN-1061’s improved safety margins were based on preclinical findings and were not yet established in clinical trials.
- The company depended heavily on ZGN-1061, third-party clinical research organizations and contract manufacturers. Manufacturing processes were still being optimized, were not validated for commercialization, and there were no long-term supply agreements.
- Zafgen anticipated continuing operating losses and eventual need for additional capital to complete development and pursue commercialization. Financing could dilute shareholders, add debt restrictions, or require relinquishing product rights.
- A shareholder securities class action concerning statements about beloranib clinical trials had been dismissed with prejudice by the district court; plaintiffs appealed, and the appeal hearing was held March 7, 2017. The company said it could not estimate possible losses.
- The 2014 credit facility was secured by substantially all personal property other than intellectual property, bore an 8.1% stated rate and included a 6% final payment on amounts drawn. The filing reported an effective annual rate of approximately 10.8%.
- The independent auditor issued an unmodified opinion on the financial statements. Management reported disclosure controls and internal control over financial reporting were effective as of year-end; the auditor was not required to attest to internal controls because Zafgen was an emerging growth company.
Important facts for investors to verify
- Confirm the issuer identity: the supplied document is Zafgen, Inc., not Larimar Therapeutics, Inc.
- Review subsequent ZGN-1061 trial results and regulatory developments, especially safety and thrombotic-event data.
- Assess cash burn, spending plans and financing needs against the $129.2 million year-end liquidity balance and management’s stated one-year runway.
- Verify repayment and any subsequent refinancing or settlement of the credit facility, and the implications of its security and covenants.
- Check the status and outcome of the securities-litigation appeal and any related contingencies.